An example of a therapeutic agent that corrects HK2-linked metabolic dysfunction in hyperglycemia is the glyoxalase 1 (Glo1) inducer, optimized to a combination of trans-resveratrol (tRES) and hesperetin (HESP), or tRES-HESP (237). The gene discussed is HK2; the disease is Hyperglycemia.